2020 started with a global coronavirus crisis that has created a new global deal making landscape in which the biopharma industry is playing a relevant role and immersed in a race for finding a treatment or vaccine for this infectious disease. During Q1 2020, mergers and acquisitions (M&A) activity in biopharma markets increased its volume compared to the same quarter of 2019 (an increase of 6.4%). However, megadeals did not have the same presence during this quarter and is reflected in the drop of the top ten value from $115 billion in Q1 2019 to $20.5 billion in Q1 2020 (a decline of 82%). Licenses were in abundance with the top 10 licensing deals in Q1 2020 having a disclosed deal value of $19.4 billion, a decrease of 24% from $25.6 billion in the same quarter the previous year.
This report looks at some key M&As and licensing deals in Q1 of 2020, using data analysis from Clarivate’s Cortellis pharma drugs and deals intelligence platform.
Fill out the form to get more details on key M&A and licensing deals, a deep dive into APAC, and the impact of COVID-19 on the deal making space.